ES2308962T3 - Vacunas que comprenden un conjugado de antigeno polisacarido-proteina transportadora y una proteina transportadora libre. - Google Patents

Vacunas que comprenden un conjugado de antigeno polisacarido-proteina transportadora y una proteina transportadora libre. Download PDF

Info

Publication number: ES2308962T3
Authority: ES; Spain
Prior art keywords: vaccine; antigen; polysaccharide; diphtheria; combined vaccine
Prior art date: 1995-06-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES00203772T

Other languages

English (en)

Spanish (es)

Inventor

Moncef Mohamed Smithkline Beecham Biol. Sa Slaoui

Pierre SmithKline Beecham Biologicals s.a Hauser

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GlaxoSmithKline Biologicals SA

Original Assignee

GlaxoSmithKline Biologicals SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-04

Publication date

2008-12-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2308962(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-23 Priority claimed from GBGB9512827.8A external-priority patent/GB9512827D0/en

1995-07-01 Priority claimed from GBGB9513443.3A external-priority patent/GB9513443D0/en

1995-12-15 Priority claimed from GBGB9525657.4A external-priority patent/GB9525657D0/en

1996-06-04 Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA

2008-12-16 Application granted granted Critical

2008-12-16 Publication of ES2308962T3 publication Critical patent/ES2308962T3/es

2016-06-04 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 61
102000036639 antigens Human genes 0.000 title claims abstract description 30
108091007433 antigens Proteins 0.000 title claims abstract description 30
239000000427 antigen Substances 0.000 title claims abstract description 29
108090000623 proteins and genes Proteins 0.000 title description 12
102000004169 proteins and genes Human genes 0.000 title description 12
229920001282 polysaccharide Polymers 0.000 claims abstract description 42
239000005017 polysaccharide Substances 0.000 claims abstract description 42
150000004676 glycans Chemical class 0.000 claims abstract description 41
108010078791 Carrier Proteins Proteins 0.000 claims abstract description 23
102000014914 Carrier Proteins Human genes 0.000 claims abstract description 9
241000588650 Neisseria meningitidis Species 0.000 claims abstract description 3
241000193998 Streptococcus pneumoniae Species 0.000 claims abstract description 3
229940031000 streptococcus pneumoniae Drugs 0.000 claims abstract 2
206010013023 diphtheria Diseases 0.000 claims description 11
206010043376 Tetanus Diseases 0.000 claims description 10
229960000814 tetanus toxoid Drugs 0.000 claims description 10
229960003983 diphtheria toxoid Drugs 0.000 claims description 7
201000005702 Pertussis Diseases 0.000 claims description 6
239000002671 adjuvant Substances 0.000 claims description 5
208000015181 infectious disease Diseases 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 3
230000003000 nontoxic effect Effects 0.000 claims description 3
241000700721 Hepatitis B virus Species 0.000 claims description 2
241000709721 Hepatovirus A Species 0.000 claims description 2
208000000474 Poliomyelitis Diseases 0.000 claims description 2
230000036039 immunity Effects 0.000 claims description 2
230000001681 protective effect Effects 0.000 claims description 2
239000003053 toxin Substances 0.000 claims description 2
231100000765 toxin Toxicity 0.000 claims description 2
208000035473 Communicable disease Diseases 0.000 claims 1
239000000203 mixture Substances 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
208000002672 hepatitis B Diseases 0.000 description 8
230000002163 immunogen Effects 0.000 description 7
238000000034 method Methods 0.000 description 7
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
241000700159 Rattus Species 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
230000004044 response Effects 0.000 description 5
229940001442 combination vaccine Drugs 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
AIHDUTVBOYDXOW-UHFFFAOYSA-N 4-(dimethylamino)pyridin-1-ium-1-carbonitrile Chemical compound CN(C)C1=CC=[N+](C#N)C=C1 AIHDUTVBOYDXOW-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
229960000074 biopharmaceutical Drugs 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
231100000283 hepatitis Toxicity 0.000 description 3
239000000463 material Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
-1 tetrafluoroborate 1-cyano-4-dimethylaminopyridinium Chemical compound 0.000 description 3
108010060123 Conjugate Vaccines Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241000991587 Enterovirus C Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000606768 Haemophilus influenzae Species 0.000 description 2
229940124914 Havrix Drugs 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000036755 cellular response Effects 0.000 description 2
229940031670 conjugate vaccine Drugs 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
239000004643 cyanate ester Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
208000005252 hepatitis A Diseases 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
229940031348 multivalent vaccine Drugs 0.000 description 2
108010021711 pertactin Proteins 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000004224 protection Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
150000003568 thioethers Chemical class 0.000 description 2
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
229910017119 AlPO Inorganic materials 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000589968 Borrelia Species 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
229940124884 Engerix-B Drugs 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
241000724675 Hepatitis E virus Species 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
229940124915 Infanrix Drugs 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
241001092142 Molina Species 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
238000011672 OFA rat Methods 0.000 description 1
241000224016 Plasmodium Species 0.000 description 1
241001454523 Quillaja saponaria Species 0.000 description 1
235000009001 Quillaja saponaria Nutrition 0.000 description 1
101000999689 Saimiriine herpesvirus 2 (strain 11) Transcriptional regulator ICP22 homolog Proteins 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
201000005010 Streptococcus pneumonia Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
241000223996 Toxoplasma Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
229940031567 attenuated vaccine Drugs 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
229940045808 haemophilus influenzae type b Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
230000006698 induction Effects 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
101710130522 mRNA export factor Proteins 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
229940035032 monophosphoryl lipid a Drugs 0.000 description 1
229940031346 monovalent vaccine Drugs 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
229960005323 phenoxyethanol Drugs 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000001012 protector Effects 0.000 description 1
239000013014 purified material Substances 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
102000012498 secondary active transmembrane transporter activity proteins Human genes 0.000 description 1
108040003878 secondary active transmembrane transporter activity proteins Proteins 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ES00203772T 1995-06-07 1996-06-04 Vacunas que comprenden un conjugado de antigeno polisacarido-proteina transportadora y una proteina transportadora libre. Expired - Lifetime ES2308962T3 (es)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US47263995A	1995-06-07	1995-06-07
US472639		1995-06-07
GBGB9512827.8A GB9512827D0 (en)	1995-06-23	1995-06-23	Vaccines
GB9512827		1995-06-23
GB9513443		1995-07-01
GBGB9513443.3A GB9513443D0 (en)	1995-07-01	1995-07-01	Vaccines
GB9525657		1995-12-15
GBGB9525657.4A GB9525657D0 (en)	1995-12-15	1995-12-15	Vaccines

Publications (1)

Publication Number	Publication Date
ES2308962T3 true ES2308962T3 (es)	2008-12-16

Family

ID=27451300

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES00203772T Expired - Lifetime ES2308962T3 (es)	1995-06-07	1996-06-04	Vacunas que comprenden un conjugado de antigeno polisacarido-proteina transportadora y una proteina transportadora libre.
ES96920790T Expired - Lifetime ES2164251T5 (es)	1995-06-07	1996-06-04	Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES96920790T Expired - Lifetime ES2164251T5 (es)	1995-06-07	1996-06-04	Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.

Country Status (18)

Country	Link
EP (2)	EP0831901B2 (2)
JP (2)	JP4233113B2 (2)
AT (2)	ATE205724T1 (2)
AU (1)	AU695720B2 (2)
BR (1)	BR9608612A (2)
CA (1)	CA2221511C (2)
CZ (1)	CZ390297A3 (2)
DE (2)	DE69615362T3 (2)
DK (1)	DK1090642T3 (2)
ES (2)	ES2308962T3 (2)
HU (1)	HUP9802199A3 (2)
IL (1)	IL122431A0 (2)
NO (1)	NO975555L (2)
NZ (1)	NZ311000A (2)
PT (1)	PT1090642E (2)
SI (1)	SI1090642T1 (2)
TR (1)	TR199701547T1 (2)
WO (1)	WO1996040242A1 (2)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6696065B1 (en)	1995-05-04	2004-02-24	Aventis Pastuer Limited	Acellular pertussis vaccines and methods of preparation thereof
NZ311000A (en) *	1995-06-07	1999-04-29	Smithkline Beecham Biolog	Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein
CA2259415A1 (en) *	1996-07-02	1998-01-08	Connaught Laboratories Limited	Multivalent dtp-polio vaccines
US6248334B1 (en)	1997-01-08	2001-06-19	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US6284250B1 (en)	1998-02-05	2001-09-04	The Henry M. Jackson Foundation For The Advancement Of Military Medicine	Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
US7018637B2 (en) *	1998-02-23	2006-03-28	Aventis Pasteur, Inc	Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
JP2002539273A (ja)	1999-03-19	2002-11-19	スミスクラインビーチャムバイオロジカルズソシエテアノニム	ワクチン
FR2806304B1 (fr) *	2000-03-17	2002-05-10	Aventis Pasteur	Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
PT2332581E (pt)	2001-01-23	2015-10-16	Sanofi Pasteur Inc	Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
CN1809380B (zh)	2002-10-11	2010-05-12	启龙有限公司	广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
MXPA05004528A (es)	2002-11-01	2005-07-26	Glaxosmithkline Biolog Sa	Composicion inmunogenica.
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
ES2461350T3 (es)	2003-01-30	2014-05-19	Novartis Ag	Vacunas inyectables contra múltiples serogrupos de meningococos
CA2744997A1 (en)	2003-09-26	2005-04-07	Exelixis, Inc.	C-met modulators and method of use
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
NZ546430A (en)	2003-10-02	2009-04-30	Novartis Vaccines & Diagnostic	Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en)	2004-03-17	2004-04-21	Chiron Srl	Analysis of saccharide vaccines without interference
US9402915B2 (en)	2004-04-30	2016-08-02	Glaxosmithkline Biologicals Sa	Integration of meningococcal conjugate vaccination
GB0409745D0 (en) *	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
GB0411387D0 (en)	2004-05-21	2004-06-23	Chiron Srl	Analysis of saccharide length
GB0413868D0 (en)	2004-06-21	2004-07-21	Chiron Srl	Dimensional anlaysis of saccharide conjugates
GB0428394D0 (en) *	2004-12-24	2005-02-02	Chiron Srl	Saccharide conjugate vaccines
GB0502096D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Purification of streptococcal capsular polysaccharide
GB0502095D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Conjugation of streptococcal capsular saccharides
GB0505518D0 (en)	2005-03-17	2005-04-27	Chiron Srl	Combination vaccines with whole cell pertussis antigen
BRPI0610297A2 (pt)	2005-04-18	2010-06-08	Novartis Vaccines & Diagnostic	expressão de antìgeno de superfìcie de vìrus da hepatite b para a preparação de vacina
LT2351578T (lt)	2005-06-27	2017-04-10	Glaxosmithkline Biologicals S.A.	Vakcinų gavimo būdas
EP2308504A3 (en)	2005-09-01	2011-11-30	Novartis Vaccines and Diagnostics GmbH	Multiple vaccines including serogroup C meningococcus
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
US10828361B2 (en)	2006-03-22	2020-11-10	Glaxosmithkline Biologicals Sa	Regimens for immunisation with meningococcal conjugates
ES2383209T3 (es)	2006-03-22	2012-06-19	Novartis Ag	Regímenes para la inmunización con conjugados meningococicos
EA015964B1 (ru)	2006-09-07	2012-01-30	Глаксосмитклайн Байолоджикалс С.А.	Вакцина
GB0700136D0 (en)	2007-01-04	2007-02-14	Glaxosmithkline Biolog Sa	Process for manufacturing vaccines
CN102264444B (zh)	2008-10-27	2015-08-05	诺华股份有限公司	纯化方法
GB0822633D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Formulation
GB0822634D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Meningitis vaccines
EP2493510B1 (en)	2009-09-30	2020-07-08	GlaxoSmithKline Biologicals SA	Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
PL2493498T3 (pl)	2009-10-30	2017-08-31	Glaxosmithkline Biologicals Sa	Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
US9173954B2 (en)	2009-12-30	2015-11-03	Glaxosmithkline Biologicals Sa	Polysaccharide immunogens conjugated to E. coli carrier proteins
WO2012020326A1 (en)	2010-03-18	2012-02-16	Novartis Ag	Adjuvanted vaccines for serogroup b meningococcus
EP2612148B1 (en)	2010-09-04	2019-06-12	GlaxoSmithKline Biologicals SA	Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
GB201101665D0 (en)	2011-01-31	2011-03-16	Novartis Ag	Immunogenic compositions
WO2012085668A2 (en)	2010-12-24	2012-06-28	Novartis Ag	Compounds
US20140112950A1 (en)	2011-03-02	2014-04-24	Manmohan Singh	Combination vaccines with lower doses of antigen and/or adjuvant
GB201106340D0 (en) *	2011-04-14	2011-06-01	Isis Innovation	Composition
EP2755683B1 (en)	2011-09-14	2019-04-03	GlaxoSmithKline Biologicals SA	Methods for making saccharide-protein glycoconjugates
WO2013068949A1 (en)	2011-11-07	2013-05-16	Novartis Ag	Carrier molecule comprising a spr0096 and a spr2021 antigen
EP2592137A1 (en)	2011-11-11	2013-05-15	Novartis AG	Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011118371B4 (de)	2011-11-11	2014-02-13	Novartis Ag	Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de)	2011-11-11	2014-12-24	Novartis Ag	Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB2495341B (en)	2011-11-11	2013-09-18	Novartis Ag	Fermentation methods and their products
GB201121301D0 (en)	2011-12-12	2012-01-25	Novartis Ag	Method
JP2015509963A (ja)	2012-03-08	2015-04-02	ノバルティスアーゲー	Ｔｌｒ４アゴニストを含む混合ワクチン
RU2014151567A (ru)	2012-05-22	2016-07-10	Новартис Аг	Конъюгат менингококка серогруппы х
EP2892553A1 (en)	2012-09-06	2015-07-15	Novartis AG	Combination vaccines with serogroup b meningococcus and d/t/p
AR092896A1 (es)	2012-10-03	2015-05-06	Novartis Ag	Composiciones inmunogenicas
CA2886938A1 (en)	2012-10-12	2014-04-17	Glaxosmithkline Biologicals S.A.	Non-cross-linked acellular pertussis antigens for use in combination vaccines
US20150320852A1 (en)	2012-12-18	2015-11-12	Glaxosmithkline Biologicals Sa	Conjugates for protecting against diphtheria and/or tetanus
ES2843509T3 (es)	2013-01-04	2021-07-19	Obi Pharma Inc	Vacunas con mayor densidad de antígeno carbohidratado y nuevo adyuvante de saponina
CN104174019A (zh) *	2014-09-23	2014-12-03	成都康华生物制品有限公司	四价脑膜炎球菌多糖载体蛋白结合疫苗
US9815886B2 (en)	2014-10-28	2017-11-14	Adma Biologics, Inc.	Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en)	2014-12-19	2016-06-22	Novartis AG	Purification of streptococcal capsular polysaccharide
EP3439704A1 (en)	2016-04-05	2019-02-13	GSK Vaccines S.r.l.	Immunogenic compositions
EP3530285B1 (en)	2016-10-20	2023-08-09	KM Biologics Co., Ltd.	METHOD FOR PRODUCING HIB CONJUGATE VACCINE USING PRP WITH LOWERED MOLECULAR WEIGHT
US10259865B2 (en)	2017-03-15	2019-04-16	Adma Biologics, Inc.	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3799884A1 (en)	2019-10-01	2021-04-07	GlaxoSmithKline Biologicals S.A.	Immunogenic compositions
US11173199B2 (en) *	2019-11-13	2021-11-16	Alopexx Inc.	Low contaminant compositions
WO2021174330A1 (en) *	2020-03-05	2021-09-10	Nuecology Biomedical Inc.	Amphiphilic alginate-oleic acid macromolecules and process for preparation therof
CN116847879A (zh)	2020-11-13	2023-10-03	葛兰素史密丝克莱恩生物有限公司	细菌蛋白载体和缀合方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4902506A (en) *	1983-07-05	1990-02-20	The University Of Rochester	Immunogenic conjugates
US4644059A (en) *	1982-07-06	1987-02-17	Connaught Laboratories, Inc.	Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
IT1187753B (it) *	1985-07-05	1987-12-23	Sclavo Spa	Coniugati glicoproteici ad attivita' immunogenica trivalente
ATE121947T1 (de) *	1989-12-14	1995-05-15	Ca Nat Research Council	Verbessertes meningokokkale polysaccharidkonjugatvakzin.
ZA937034B (en) *	1992-09-24	1995-06-23	Brigham & Womens Hospital	Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
ES2126616T3 (es) *	1992-10-27	1999-04-01	American Cyanamid Co	Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna.
NZ311000A (en) *	1995-06-07	1999-04-29	Smithkline Beecham Biolog	Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein

1996
- 1996-06-04 NZ NZ311000A patent/NZ311000A/en unknown
- 1996-06-04 PT PT00203772T patent/PT1090642E/pt unknown
- 1996-06-04 SI SI9630763T patent/SI1090642T1/sl unknown
- 1996-06-04 AT AT96920790T patent/ATE205724T1/de not_active IP Right Cessation
- 1996-06-04 WO PCT/EP1996/002436 patent/WO1996040242A1/en not_active Ceased
- 1996-06-04 BR BR9608612A patent/BR9608612A/pt unknown
- 1996-06-04 DE DE69615362T patent/DE69615362T3/de not_active Expired - Lifetime
- 1996-06-04 AU AU62221/96A patent/AU695720B2/en not_active Ceased
- 1996-06-04 EP EP96920790A patent/EP0831901B2/en not_active Expired - Lifetime
- 1996-06-04 EP EP00203772A patent/EP1090642B8/en not_active Revoked
- 1996-06-04 DE DE69637597T patent/DE69637597D1/de not_active Expired - Lifetime
- 1996-06-04 HU HU9802199A patent/HUP9802199A3/hu unknown
- 1996-06-04 AT AT00203772T patent/ATE400295T1/de active
- 1996-06-04 DK DK00203772T patent/DK1090642T3/da active
- 1996-06-04 JP JP50014697A patent/JP4233113B2/ja not_active Expired - Lifetime
- 1996-06-04 CZ CZ973902A patent/CZ390297A3/cs unknown
- 1996-06-04 ES ES00203772T patent/ES2308962T3/es not_active Expired - Lifetime
- 1996-06-04 IL IL12243196A patent/IL122431A0/xx unknown
- 1996-06-04 TR TR97/01547T patent/TR199701547T1/xx unknown
- 1996-06-04 ES ES96920790T patent/ES2164251T5/es not_active Expired - Lifetime
- 1996-06-04 CA CA2221511A patent/CA2221511C/en not_active Expired - Lifetime
1997
- 1997-12-02 NO NO975555A patent/NO975555L/no unknown
2007
- 2007-03-12 JP JP2007061946A patent/JP4653131B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU695720B2 (en)	1998-08-20
CZ390297A3 (cs)	1998-05-13
ES2164251T3 (es)	2002-02-16
HUP9802199A1 (hu)	1999-01-28
JP4233113B2 (ja)	2009-03-04
DE69615362D1 (de)	2001-10-25
DE69615362T3 (de)	2006-07-20
DK1090642T3 (da)	2008-09-22
JP4653131B2 (ja)	2011-03-16
SI1090642T1 (sl)	2008-12-31
JPH11507026A (ja)	1999-06-22
DE69615362T2 (de)	2002-06-13
BR9608612A (pt)	1999-05-04
ES2164251T5 (es)	2006-06-01
EP1090642B8 (en)	2010-08-11
PT1090642E (pt)	2008-09-09
ATE400295T1 (de)	2008-07-15
HUP9802199A3 (en)	1999-07-28
EP0831901B1 (en)	2001-09-19
WO1996040242A1 (en)	1996-12-19
EP1090642B1 (en)	2008-07-09
CA2221511A1 (en)	1996-12-19
ATE205724T1 (de)	2001-10-15
CA2221511C (en)	2013-01-08
IL122431A0 (en)	1998-06-15
TR199701547T1 (xx)	1998-03-21
MX9709732A (es)	1998-10-31
EP0831901B2 (en)	2005-12-07
JP2007186524A (ja)	2007-07-26
DE69637597D1 (de)	2008-08-21
NO975555D0 (no)	1997-12-02
AU6222196A (en)	1996-12-30
NO975555L (no)	1998-01-09
EP1090642A2 (en)	2001-04-11
EP1090642A3 (en)	2001-08-22
EP0831901A1 (en)	1998-04-01
NZ311000A (en)	1999-04-29

Publication	Publication Date	Title
ES2164251T5 (es)	2006-06-01	Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.
ES2157447T5 (es)	2011-04-29	Una composición de vacuna que comprende un antígeno conjugado de polisacárido de haemofilus influenzae tipo b adsorbido en fosfato de aluminio.
ES2334181T3 (es)	2010-03-05	Vacunas combinadas que comprenden antigeno de superficie de la hepatitis b y otros antigenos.
ES2240647T7 (es)	2010-03-31	Vacuna de pertussis acelular con toxoides de difteria y tetanos.
US6756040B2 (en)	2004-06-29	Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminum phosphate
US20050129707A1 (en)	2005-06-16	Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
KR19990022680A (ko)	1999-03-25	폴리사카라이드 항원-담체 단백질 콘쥬게이트 및유리 담체단백질을 포함하는 백신
ES2224252T3 (es)	2005-03-01	Composicion de vacuna que comprende fragmentos de la proteina de membrana externa de bordetella pertussis.
MXPA97009732A (en)	1999-01-11	Vaccine comprising a conjugate of antigen depolisacarido protein carrier and protein carrier li
PL174077B1 (pl)	1998-06-30	Szczepionka do ochrony przed zakażeniem lub leczeniem zakażeń Hepatitis B i heterologicznych chorób, zawierająca antygen powierzchniowy Hepatitis B (HBsAg)
MXPA97010521A (en)	1998-11-12	A composition of vaccines including an antigen conjugated of polysaccharid adsorbided in alumi phosphate
HK1037516B (en)	2010-01-22	A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate